Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | EXS74539 |
| Synonyms | |
| Therapy Description |
EXS74539 (REC-4539) is a reversible LSD1 inhibitor that modulates gene expression, which may lead to decreased tumor cell proliferation and inhibition of tumor growth (Cancer Res (2023) 83 (7_Supplement): 6290). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| EXS74539 | EXS 74539|EXS-74539|REC-4539|REC4539|REC 4539 | EXS74539 (REC-4539) is a reversible LSD1 inhibitor that modulates gene expression, which may lead to decreased tumor cell proliferation and inhibition of tumor growth (Cancer Res (2023) 83 (7_Supplement): 6290). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07517198 | Phase I | EXS74539 | Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors | Recruiting | USA | 0 |